ALT
Altimmune, Inc.
There isn't enough reported data to score ALT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ALT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALT's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALT PE Valuation
ALT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ALT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ALT's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ALT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.71 | +$0.36 |
| Q2 2026 | -$0.77 | +$0.41 |
| Q1 2026 | -$0.92 | +$0.34 |
| Q4 2025 | -$1.00 | +$0.34 |
| Q3 2025 | -$1.07 | +$0.50 |
| Q2 2025 | -$1.18 | +$0.46 |
| Q1 2025 | -$1.26 | +$0.35 |
| Q4 2024 | -$1.34 | +$0.32 |
ALT is still losing money, but far less than before: $0.71 per share over the past year, against $2.41 at its worst in early 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ALT on earnings quality, reporting a profit while its opponent remains loss making.
ALT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $26K | +420% |
| Q3 2025 | $5K | 0% |
| Q2 2025 | $5K | 0% |
| Q1 2025 | $5K | 0% |
| Q4 2024 | $5K | -86% |
| Q3 2024 | $5K | -99% |
| Q2 2024 | $5K | -17% |
| Q1 2024 | $5K | -76% |
ALT has the stronger quarterly revenue trend. Revenue is up 420% for ALT versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -111127% | +386193 points |
| Q3 2025 | -417180% | +78160 points |
| Q2 2025 | -458440% | +76460 points |
| Q1 2025 | -436300% | +99580 points |
| Q4 2024 | -497320% | -406447 points |
| Q3 2024 | -495340% | -489114 points |
| Q2 2024 | -534900% | -234783 points |
| Q1 2024 | -535880% | -432266 points |
ALT's operating margin was −111127% last quarter, up 386193 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ALT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.8M | -$25.9M |
| Q1 2026 | -$21M | -$4.1M |
| Q4 2023 | -$16.5M | +$811K |
| Q3 2023 | -$20.5M | -$5.4M |
| Q2 2023 | -$19.4M | -$2.7M |
| Q1 2023 | -$19.5M | -$5.9M |
| Q4 2022 | -$17.3M | +$4.8M |
| Q3 2022 | -$15.1M | +$2.7M |
ALT has burned cash in almost every quarter: −$102M over the past year, against −$66M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ALT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +19.8M shares |
| 1 year | +152% | +124M shares |
| 3 years | +310% | +155M shares |
| 5 years | +427% | +166M shares |
| Available history | +1464% | +192M shares |
ALT has 205M diluted shares, up 152% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ALT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ALT Net Leverage
ALT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ALT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 4.7 | Oversold |
ALT's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ALT PE vs Healthcare Sector
ALT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ALT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.31 | 30% below |
| 20 week MA | $2.77 | 42% below |
| 50 week MA | $3.33 | 52% below |
| 100 week MA | $4.23 | 62% below |
| 200 week MA | $5.48 | 71% below |
ALT is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ALT on trend strength, trading above more of its moving averages.
ALT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.80 | $11.5 | +536% |
| 2021 | $11.5 | $9.20 | -20% |
| 2022 | $9.20 | $15.3 | +67% |
| 2023 | $15.3 | $11.3 | -27% |
| 2024 | $11.3 | $7.67 | -32% |
| 2025 | $7.67 | $3.86 | -50% |
| 2026 YTD | $3.86 | $1.61 | -58% |
ALT has finished three years in a row lower, and it's down 58% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ALT on returns for 2026, with the stronger performance.